everolimus — CareFirst (Caremark)
Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (previously treated)
Initial criteria
- Used as single-agent therapy for previously treated disease
Reauthorization criteria
- Continuation may be approved when no unacceptable toxicity or disease progression
Approval duration
12 months